Cargando…

Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis

BACKGROUND: Efficacy and safety data of COVID-19 vaccines among cancer populations have been limited; however, preliminary data from recent studies have emerged regarding their immunogenicity and safety in this population. In this review, we examined current peer-reviewed publications containing ser...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tran, Son, Truong, Tony H., Narendran, Aru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542448/ https://www.ncbi.nlm.nih.gov/pubmed/34798454 http://dx.doi.org/10.1016/j.ejca.2021.10.013

Ejemplares similares

Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies
por: Reynolds, Carson R., et al.
Publicado: (2022)

Aurora Kinases as Druggable Targets in Pediatric Leukemia: Heterogeneity in Target Modulation Activities and Cytotoxicity by Diverse Novel Therapeutic Agents
por: Jayanthan, Aarthi, et al.
Publicado: (2014)

The Developmental Origins of Cancer: A Review of the Genes Expressed in Embryonic Cells with Implications for Tumorigenesis
por: Balachandran, Savitha, et al.
Publicado: (2023)

Survivin as a Preferential Target for Cancer Therapy
por: Mobahat, Mahsa, et al.
Publicado: (2014)

Identification of Altered Primary Immunodeficiency-Associated Genes and Their Implications in Pediatric Cancers
por: Standing, Shaelene, et al.
Publicado: (2022)

Interim statement on covid-19 vaccine booster doses
Publicado: (2021)

Interim statement on covid-19 vaccine booster doses
Publicado: (2021)

Lin28A/let-7 oncogenic circuit is a potential therapeutic target in neurocutaneous melanosis-associated CNS tumors in children
por: Jain, Mohit, et al.
Publicado: (2020)

Interim estimates in null models of COVID-19 vaccine effectiveness
por: Lisewski, Andreas Martin
Publicado: (2021)

COVID-19 vaccine and boosted immunity: Nothing ad interim to do?
por: Roncati, Luca, et al.
Publicado: (2020)

Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization
por: Patel, Minal K., et al.
Publicado: (2021)

The hepatocyte growth factor/mesenchymal epithelial transition factor axis in high-risk pediatric solid tumors and the anti-tumor activity of targeted therapeutic agents
por: Grundy, Megan, et al.
Publicado: (2022)

Tracking the uptake and trajectory of COVID-19 vaccination coverage in 15 West African countries: an interim analysis
por: Afolabi, Muhammed Olanrewaju, et al.
Publicado: (2021)

ATRT-09. IDENTIFICATION OF POTENTIAL GENETIC DRIVERS OF METHOTREXATE (MTX) RESISTANCE IN ATYPICAL TERATOID RHABDOID TUMOURS (ATRT) THROUGH A GENOME-WIDE RNAI SCREEN
por: Kannappan, Sunand, et al.
Publicado: (2021)

Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on vaccine safety on AstraZeneca COVID-19 vaccine
Publicado: (2021)

Interim Guidelines on Antiviral Therapy for COVID-19
por: Kim, Sun Bean, et al.
Publicado: (2020)

The Small-Molecule E26-Transformation-Specific Inhibitor TK216 Attenuates the Oncogenic Properties of Pediatric Leukemia
por: Sharma, Ritul, et al.
Publicado: (2023)

Interim Estimates of COVID-19 Vaccine Effectiveness in a Mass Vaccination Setting: Data from an Italian Province
por: Flacco, Maria Elena, et al.
Publicado: (2021)

Interim results of an ecological experiment — Conjugate vaccination against the pneumococcus and serotype replacement
por: Hausdorff, William P, et al.
Publicado: (2016)

Guidance on interim analysis methods in clinical trials
por: Ciolino, Jody D., et al.
Publicado: (2023)

Editorial. COVID-19 and neurosurgical practice: an interim report
por: Amin-Hanjani, Sepideh, et al.
Publicado: (2020)

The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia
por: Meier-Stephenson, Vanessa, et al.
Publicado: (2017)

Outcomes in Patients with Hematologic Disease and COVID-19 in Russia: Interim Analysis of CHRONOS19 Registry
por: Gavrilina, Olga A., et al.
Publicado: (2020)

Temporal order of cancers and mental disorders in an adult population
por: Cawthorpe, David, et al.
Publicado: (2018)

Monkeypox outbreak, vaccination, and treatment implications for the dermatologic patient: Review and interim guidance from the Medical Dermatology Society
por: Kumar, Anusha M., et al.
Publicado: (2023)

Targeted inhibition of MEK1 by cobimetinib leads to differentiation and apoptosis in neuroblastoma cells
por: Singh, Anjali, et al.
Publicado: (2015)

Potent in vitro and xenograft antitumor activity of a novel agent, PV-10, against relapsed and refractory neuroblastoma
por: Swift, Lucy, et al.
Publicado: (2019)

Interim Singapore guidelines for basic and advanced life support for paediatric patients with suspected or confirmed COVID-19
por: Ong, Gene Yong-Kwang, et al.
Publicado: (2021)

CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report
por: Baumann, Tycho, et al.
Publicado: (2020)

Interim Guidance for Urodynamic Practice during COVID-19 Pandemic
por: Figueiredo, André Avarese, et al.
Publicado: (2020)

ISTH interim guidance on recognition and management of coagulopathy in COVID‐19
por: Thachil, Jecko, et al.
Publicado: (2020)

Interim thymus and activation regulated chemokine versus interim (18)F‐fluorodeoxyglucose positron‐emission tomography in classical Hodgkin lymphoma response evaluation
por: Plattel, Wouter J., et al.
Publicado: (2020)

The Advisory Committee on Immunization Practices’ Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine — United States, 2020
por: Dooling, Kathleen, et al.
Publicado: (2020)

The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020
por: Dooling, Kathleen, et al.
Publicado: (2021)

Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings
por: Iwata, Satoshi, et al.
Publicado: (2022)

Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico
por: Ponce-de-León, Samuel, et al.
Publicado: (2023)

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
por: Monin, Leticia, et al.
Publicado: (2021)

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020
por: Oliver, Sara E., et al.
Publicado: (2021)

Structures - Interim Note
por: Sicard, C H
Publicado: (1983)

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021
por: Oliver, Sara E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6v58ofq4he3thu7fdcnhoml76g